Aslan Total Liabilities Trend from 2010 to 2021

ASLN -  USA Stock  

USD 1.30  0.14  9.72%

Aslan Pharmaceuticals Total Liabilities yearly trend continues to be quite stable with very little volatility. The value of Total Liabilities is projected to decrease to about 25.4 M. From the period between 2010 and 2021, Aslan Pharmaceuticals, Total Liabilities regression line of its data series had standard deviation of 6,006,466 and standard deviation of  6,006,466. Aslan Pharmaceuticals Operating Expenses is quite stable at the moment as compared to the past year. The company's current value of Operating Expenses is estimated at 16.92 Million. Research and Development Expense is expected to rise to about 13.4 M this year, although the value of Consolidated Income will most likely fall to (19.1 M).

Aslan Historical Trends 

Check Aslan Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Aslan main balance sheet or income statement drivers, such as Cost of Revenue of 400.6 K, Gross Profit of 2.4 M or Interest Expense of 1.1 M, as well as many exotic indicators such as Asset Turnover of 0.0707, Current Ratio of 1.49 or Gross Margin of 0.8. Aslan financial statements analysis is a perfect complement when working with Aslan Pharmaceuticals Valuation or Volatility modules. It can also supplement various Aslan Pharmaceuticals Technical models. Please continue to the analysis of Aslan Pharmaceuticals Correlation against competitors.

Aslan Pharmaceuticals Quarterly Total Liabilities

36.95 MillionShare

Aslan Total Liabilities Breakdown

Showing smoothed Total Liabilities of Aslan Pharmaceuticals with missing and latest data points interpolated. Deferred Income Tax is recorded on Aslan Pharmaceuticals balance sheet and a result of income already earned and recognized for accounting, but not tax, purposes. Also, differences between tax laws and accounting methods can result in a temporary difference in the amount of income tax payable by a company. This difference is recorded on Aslan Pharmaceuticals books as deferred income tax. Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Principal components are Total Debt; [DeferredRev]; Trade and Non Trade Payables; Deposit Liabilities; and Tax Liabilities.Aslan Pharmaceuticals' Total Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Aslan Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Total Liabilities10 Years Trend
Slightly volatile
 Total Liabilities 

Aslan Total Liabilities Regression Statistics

Arithmetic Mean 16,556,517
Geometric Mean 15,666,797
Coefficient Of Variation 36.28
Mean Deviation 5,276,207
Median 12,139,230
Standard Deviation 6,006,466
Range 14,094,804
R-Value 0.88
R-Squared 0.77
Significance 0.00018559
Slope 1,459,609

Aslan Total Liabilities History

201715.8 M
201822.3 M
201924 M
202026.2 M
202125.4 M

About Aslan Pharmaceuticals Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Aslan Pharmaceuticals income statement, its balance sheet, and the statement of cash flows. Aslan Pharmaceuticals investors use historical funamental indicators, such as Aslan Pharmaceuticals's Total Liabilities, to determine how well the company is positioned to perform in the future. Although Aslan Pharmaceuticals investors may use each financial statement separately, they are all related. The changes in Aslan Pharmaceuticals's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Aslan Pharmaceuticals's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Aslan Pharmaceuticals Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Aslan Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for 2021
Total Liabilities26.2 M25.4 M
ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company was founded in 2010 and is headquartered in Singapore. Aslan Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 18 people.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Aslan Pharmaceuticals without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Analyst Recommendations Now


Analyst Recommendations

Analyst recommendations and target price estimates broken down by several categories
All  Next Launch Module

Pair Trading with Aslan Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Aslan Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Aslan Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Aslan Pharmaceuticals Pair Correlation

Equities Pair Trading Analysis

Correlation analysis and pair trading evaluation for Aslan Pharmaceuticals and Bioatla. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation  
Please continue to the analysis of Aslan Pharmaceuticals Correlation against competitors. Note that the Aslan Pharmaceuticals information on this page should be used as a complementary analysis to other Aslan Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.

Complementary Tools for Aslan Stock analysis

When running Aslan Pharmaceuticals price analysis, check to measure Aslan Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aslan Pharmaceuticals is operating at the current time. Most of Aslan Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Aslan Pharmaceuticals' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Aslan Pharmaceuticals' price. Additionally, you may evaluate how the addition of Aslan Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
ETF Directory
Find actively traded Exchange Traded Funds (ETF) from around the world
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Focused Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Is Aslan Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aslan Pharmaceuticals. If investors know Aslan will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aslan Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Aslan Pharmaceuticals is measured differently than its book value, which is the value of Aslan that is recorded on the company's balance sheet. Investors also form their own opinion of Aslan Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Aslan Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aslan Pharmaceuticals' market value can be influenced by many factors that don't directly affect Aslan Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Aslan Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine Aslan Pharmaceuticals value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aslan Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.